Teva Pharmaceutical Industries (TEVA) Short term Debt (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Short term Debt across 18 years of filings, most recently posting $2.6 billion for Q1 2026.

• Quarterly Short term Debt rose 520.43% year-over-year to $2.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 billion (up 520.43% YoY) and the FY2025 annual result came in at $1.8 billion, up 2.19% from the prior year.
• Short term Debt grew to $2.6 billion in Q1 2026, from $1.8 billion in the prior quarter.
• Over five years, Short term Debt peaked at $3.1 billion in Q1 2024 and troughed at $24.0 million in Q3 2025.
• A 5-year average of $1.7 billion and a median of $1.8 billion in 2025 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2025 — Short term Debt slumped 99.07% — and 2026, when it soared 520.43%.
• Tracing TEVA's Short term Debt over 5 years: stood at $2.1 billion in 2022, then retreated by 20.72% to $1.7 billion in 2023, then rose by 6.52% to $1.8 billion in 2024, then grew by 2.19% to $1.8 billion in 2025, then surged by 43.52% to $2.6 billion in 2026.
• Business Quant data shows TEVA's Short term Debt at $2.6 billion in Q1 2026, $1.8 billion in Q4 2025, and $24.0 million in Q3 2025.